|
See related Aricept Evess orodispersible tab information |
|
|
|
Manufacturer |
Eisai |
|
Distributor |
DKSH |
|
Contents |
Donepezil HCl |
|
Indications |
Symptomatic treatment of mild, moderate & severe Alzheimer's disease & vascular dementia (dementia-associated w/ cerebrovascular disease).
Click to view Aricept Evess detailed prescribing infomation |
|
Dosage |
Adult & elderly Initially 5 mg/day in the evening (prior to retiring). Dose can be increased to 10 mg/day after at least 4-6 wk of clinical assessment in patients who tolerated treatment at 5 mg/day. Max: 10 mg/day.
Click to view Aricept Evess detailed prescribing infomation |
|
Overdosage |
View Aricept Evess overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Hypersensitivity to piperidine derivatives. Pregnancy.
Click to view Aricept Evess detailed prescribing infomation |
|
Special Precautions |
Sick-sinus syndrome, supraventricular cardiac conduction conditions, history of ulcer disease or those receiving concurrent NSAIDs, history of asthma or obstructive pulmonary disease. May impair ability to drive or operate machinery. Lactation.
Click to view Aricept Evess detailed prescribing infomation |
|
Adverse Drug Reactions |
Diarrhoea, muscle cramps, fatigue, nausea, vomiting, insomnia, headache, common cold, anorexia, hallucinations, agitation, aggressive behaviour, syncope, dizziness, abdominal disturbance, rash, pruritis, urinary incontinence, pain.
View ADR Monitoring Form |
|
Drug Interactions |
Anesth, ketoconazole, quinidine, itraconazole, erythromycin, fluoxetine, rifampicin, phenytoin, carbamazepine, alcohol, medications w/ anticholinergic activity, succinylcholine, other neuromuscular blockers or cholinergic agonists or β-blockers which have effects on cardiac conduction.
View more drug interactions with Aricept Evess |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Storage |
View Aricept Evess storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Aricept Evess description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Aricept Evess mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Special Feature |
Researched & developed in Japan by Eisai Co., LtdUS FDA Approved |
|
